ESR1 and breast cancer: By immunohistochemistry (IHC), AR is detected in 70–90% of ER+ BC, and less frequently in TNBC with variable results among studies (8–58%), possibly due to the heterogeneity of the used assays and of the positivity cut-offs [2].